Edition:
United Kingdom

People: Dynavax Technologies Corp (DVAX.OQ)

DVAX.OQ on NASDAQ Stock Exchange Capital Market

3.66USD
19 Jul 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.66
Open
$3.66
Day's High
$3.70
Day's Low
$3.56
Volume
180,360
Avg. Vol
357,264
52-wk High
$16.15
52-wk Low
$3.40

Novack, David 

Mr. David F. Novack serves as Interim Co-President, Co-Principal Executive Officer of Dynavax Technologies Corporation. Mr. Novack joined Dynavax in March 2013 as Senior Vice President, Operations and Quality. Mr. Novack was formerly with Novartis Vaccines & Diagnostics where he served since 2009 as the Global Head of Technical Operations and Supply Chain for Diagnostics and previously from 2007 to 2009 as the Global Head of Vaccine Manufacturing Strategy. Prior to Novartis, Mr. Novack was the Vice President, Business Development for Vaxin, Inc., a vaccine company, from 2004 to 2006. From 1993 until 2004, Mr. Novack worked at MedImmune, formerly Aviron, serving in several capacities including business development, manufacturing, contract operations and most recently as Senior Director, Supply Chain Operations. Previously, from 1989 to 1993, Mr. Novack was with American Cyanamid Company in various roles. Mr. Novack received a B.S. in Biology from State University of New York and an M.B.A. from Columbia University.

Basic Compensation

Total Annual Compensation, USD 401,700
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 1,295,890
Fiscal Year Total, USD 1,697,590

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Arnold Oronsky

231,767

David Novack

1,697,590

Ryan Spencer

--

Eddie Gray

4,748,840

Michael Ostrach

3,562,510

Robert Coffman

3,628,280
As Of  31 Dec 2018